Preveceutical Medical Inc C.PREV

Alternate Symbol(s): PRVCF

Healthcare Biotechnology

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity. Its Nature Identical peptides for treatment of various ailments. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

CSE:PREV - Post by User

Preveceutical Medical Inc

Bullboard Posts

Comment by CanadaCoinon Jan 08, 2019 10:20am

31 Views

Post# 29199835

RE:Due Diligence.....

Sorry, forgot to post the link to my due diligence material.....

User image

CanadaCoin wrote: There is only one thing I agree with MaryJ on.....and that is to perform full, unbiased due diligence on the companies you invest in.

For example, you cannot skirt around the fact that the BCSC [regulators] are investing PREV's involvement in a scheme with the Bridgemark Group....along with ten other Issuers on the CSE.

Here are a few excerpts from the BCSC Citation, directed towards the eleven 'Issuers'....

Staff are concerned that members of the BridgeMark Group generated profits for themselves and that the Issuers raised capital through the scheme, as follows:

(c) the Issuers issued securities through private placements to members of the BridgeMark Group relying on the consultant exemption to the prospectus requirement in section 2.24 of National Instrument 45-106 (Consultant Exemption),

(e) the Issuers paid most of the private placement funds back to members of the BridgeMark Group and kept very little of the money raised,

(g) the Issuers issued news releases informing the market they raised the full amount of the private placement when they had only retained a small portion of the funds.

I am of the personal opinion, that PREV's suit against the Bridgemark Group is deflection away from their own inappropriate actions in this case.